The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
19-Feb-19
$324 million
Target:
Aritzia Inc.
Advised the Special Committee of Aritzia, an innovative designer and retailer of fashion brands, on the secondary offering and concurrent repurchase of shares held by Berkshire Partners
06-Dec-18
$165 million
Target:
Storz & Bickel GmbH, related entities and IP
Acquiror:
Canopy Growth Corporation
Advised Canopy Growth, a leading diversified cannabis company, on its acquisition of Storz & Bickel, a premium manufacturer of vaporization devices
03-Dec-18
$4.0 billion
Target:
Assets owned by GlaxoSmithKline plc
Acquiror:
Unilever plc / Hindustan Unilever Limited
Advised GlaxoSmithKline plc, the UK listed international pharmaceutical and consumer healthcare company, on the divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc, and on the merger of GSK Consumer Healthcare Limited with Hindustan Unilever Limited
18-Nov-18
$876 million
Target:
David's Bridal
Acquiror:
N/A
Advised the Ad Hoc Group of the company's $481mm term loan with respect to the company's prepackaged Chapter 11 restructuring
01-Nov-18
$NA
Target:
Long-term lithium hydroxide offtake agreement with Mitsui & Co.
Acquiror:
Kidman Resources Limited
Advised Kidman Resources Limited, an ASX-listed hard rock lithium mining company with a 50% interest in the West Australian Mt. Holland lithium project, on a lithium hydroxide offtake agreement with Mitsui & Co., a leading global marketing and trading conglomerate based in Japan. The agreement is for an initial term of two years, plus two 2-year term extension options
24-Sep-18
$619 million
Target:
Farm Boy
Acquiror:
Empire Company Limited
Advised Empire Company Limited on the acquisition of Farm Boy, one of the most successful and fastest growing food retailers in Canada
15-Aug-18
$3.9 billion
Target:
Common shares and common share purchase warrants in Canopy Growth
Acquiror:
Constellation Brands
Advised Canopy Growth on a C$5bn investment by Constellation Brands. As consideration for the investment, Constellation received newly issued Canopy common shares and common share purchase warrants
09-Aug-18
$1.2 billion
Target:
Martabe gold and silver mine
Acquiror:
PT United Tractors Tbk
Advised EMR Capital, a specialist resources private equity manager, on the sale of the Martabe gold and silver mine to United Tractors
10-Jul-18
$229 million
Target:
Hiku Brands Company Ltd.
Acquiror:
Canopy Growth Corporation
Advised Canopy Growth, the world’s largest diversified cannabis company, on its acquisition of Hiku Brands
07-May-18
$7.1 billion
Target:
Frutarom
Acquiror:
International Flavors and Fragrances
Advised IFF, a leading innovator of specialty ingredients, on its acquisition of Frutarom, creating a global leader in Taste, Scent and Nutrition
02-May-18
$3.7 billion
Target:
Concordia International Corp.
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
27-Mar-18
$1.6 billion
Target:
Yakult
Acquiror:
Danone
Advised Danone, a leading global food & beverage company, on renewing its strategic partnership with Yakult, a global leader in probiotic beverages, as well as the sale of part of its stake in Yakult
22-Jan-18
$375 million
Target:
Lonmin
Advising Lonmin PLC, a major fully integrated producer of Platinum Group Metals, on the amendment of its debt facilities to support the review and implementation of its strategic options
30-Nov-17
$NA
Target:
MorphoSys AG
Acquiror:
I-Mab
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab
22-Feb-17
$533 million
Target:
Lion’s stake in Warrnambool Cheese and Butter Factory Company
Acquiror:
Saputo Inc.
Advised Lion (an Australian subsidiary of Kirin), on the sale of its strategic stake in Warrnambool Cheese and Butter Factory to Canadian-based Saputo, under its all cash takeover offer
13-Oct-16
$NA
Target:
Concordia International Corp
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process
05-Oct-16
$775 million
Target:
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
05-Oct-16
$NA
Target:
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
20-Jun-16
$NA
Target:
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Zydus Cadila
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
15-Jun-16
$414 million
Target:
Aegerion Pharmaceuticals
Acquiror:
QLT Inc.
Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization
11-Jun-16
$350 million
Target:
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Dr. Reddy’s Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
22-Dec-15
$NA
Target:
Hortifruti
Acquiror:
Partners Group
Advised Hortifruti, Brazil's number one premium retailer of healthy food, on the sale of a significant minority stake to Partners Group, a global private markets investment manager
09-Nov-15
$777 million
Target:
Lonmin Plc
Advised Lonmin Plc on its c.$777mm recapitalization consisting of c.$370mm of bank facilities at the Plc and in South Africa from the Company’s ten lending banks and a fully underwritten Rights Issue of c.$407mm.
27-Jul-15
$40.5 billion
Target:
Allergan Generics
Acquiror:
Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business